11.87
0.19 (1.58%)
| Previous Close | 11.68 |
| Open | 11.76 |
| Volume | 2,087 |
| Avg. Volume (3M) | 13,187 |
| Market Cap | 839,782,464 |
| Price / Earnings (TTM) | 84.75 |
| Price / Earnings (Forward) | 270.27 |
| Price / Sales | 2.42 |
| Price / Book | 3.10 |
| 52 Weeks Range |
| Profit Margin | -4.40% |
| Operating Margin (TTM) | 0.96% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 42.30% |
| Total Debt/Equity (MRQ) | 55.34% |
| Current Ratio (MRQ) | 2.76 |
| Operating Cash Flow (TTM) | 6.08 M |
| Levered Free Cash Flow (TTM) | 6.82 M |
| Return on Assets (TTM) | 1.99% |
| Return on Equity (TTM) | -6.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Pharming Group N.V. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -4.0 |
| Average | -1.00 |
|
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Institutions | 0.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mac Alpha Capital Management, Lp | 30 Jun 2026 | 2,148,144 |
| Silverberg Bernstein Capital Management Llc | 30 Jun 2026 | 41,547 |
| Knoll Capital Management, Llc | 30 Jun 2026 | 4,091 |
| Nalls Sherbakoff Group, Llc | 30 Jun 2026 | 870 |
| Optiver Holding B.V. | 30 Jun 2026 | 305 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |